12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Other News

Caliber Biotherapeutics, ImmunGene, LLS cancer news

The society provided about $6 million in funds to Valor Biotherapeutics LLC, a JV between ImmunGene and Caliber, to develop IGN002 to treat non-Hodgkin's lymphoma (NHL) in patients who are resistant to standard therapy with Rituxan...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >